康芝药业：止咳橘红颗粒药物临床试验获批准

Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for its "Cough Orange Granules" to conduct clinical trials for chronic obstructive pulmonary disease during acute exacerbation [1] Group 1 - The company has been granted a "Drug Clinical Trial Approval Notice" for its product [1] - The clinical trial will focus on the application of Cough Orange Granules for acute exacerbation of chronic obstructive pulmonary disease (phlegm-heat obstructing the lung syndrome) [1] - The company is in the process of further refining the clinical trial protocol [1]